December 18, 2014 / 6:20 AM / 4 years ago

BRIEF-Lundbeck discontinues development of desmoteplase and narrows 2014 profit guidance

Dec 18(Reuters) - H Lundbeck A/S :

* Said on Wednesday the company would discontinue further development of desmoteplase

* Said although studies confirmed the favourable safety profile of desmoteplase, it was insufficiently clear how to select patients in future prospective studies

* Alternatives for the project are being investigated

* Said decision implicates a write-down of 309 million Danish crowns ($51.26 million) in Q4 2014

* Narrowed guidance range for 2014

* Said now sees core EBIT of 1.1 billion-1.3 billion crowns versus previously expected 0.9 billion-1.4 billion crowns

* Said now sees 2014 reported EBIT of 0-0.2 billion crowns compared to previously expected 0-0.5 billion crowns for 2014

Source text for Eikon:

Further company coverage:

$1 = 6.0281 Danish crowns Gdynia Newsroom

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below